New pathways to clinical trial design are enabling more reliable, effective trials, helping to advance drug products to commercialization with fewer delays and risks. Decentralized trials are offering a more patient-centric experience for clinical trials and helping sponsors overcome notable hurdles common to traditional trials.
Recruitment challenges have afflicted the clinical trials space for years, often resulting in costly delays on the path to commercialization and preventing patients from receiving life-saving treatments in a timely manner. Patient retention is also a common challenge for clinical trial sponsors, as patients often find the demands of the trials more burdensome than beneficial. Decentralized trials enable patients to participate and receive medical treatments in their own home, lowering barriers to recruitment and retention. These innovative trials also increase the quality of trial data collected as the ease of participation often results in improved study engagement.
Learn more about the potential of decentralized trials as well as the technological and regulatory challenges which need to be considered in order to achieve success.